Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764012 | 0.85 | KMT2A (0.65) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL826024 | 0.84 | HPGD (0.51) | HPGDKMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL24474317 | 0.82 | HPGD (0.50) | HPGDKMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL13255794 | 0.82 | HPGD (0.69) | HPGDKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL31344791 | 0.82 | HPGD (0.50) | HPGDKMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL2451676 | 0.82 | ESRRB (0.55) | HPGDKDM4ELMNARAB9ANPC1 | |
| SCHEMBL31229114 | 0.82 | HPGD (0.73) | HPGDL3MBTL1KDM4EGLALMNA | |
| SCHEMBL4388479 | 0.81 | ALDH1A1 (0.65) | KMT2AMEN1L3MBTL1LMNAALDH1A1 | |
| SCHEMBL780470 | 0.81 | HPGD (0.49) | HPGDKMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL15288886 | 0.80 | KMT2A (0.44) | HPGDKMT2AMEN1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| CN-119161384-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112105607-B | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-112105607-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS HEALTH, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2019144132-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
| US-11384068-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | HPGD 510/4885KMT2A 3309/4885MEN1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.